Increased PD-1-levels on T cells in CML patients (mostly CD8+ T cells) have been described to correlate with potential adverse effects on the disease course [27, 28]. The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.